Palisade Bio Execs to Present at Piper Sandler Immunology Symposium
Event summary
- Palisade Bio CEO JD Finley and CMO Dr. Mitchell Jones to participate in a virtual fireside chat on February 12, 2026, at the Piper Sandler Virtual Novel Targets in Immunology Symposium.
- Management will also engage in one-on-one meetings with qualified investors during the event.
- Palisade Bio's lead program, PALI-2108, achieved a 100% clinical response in a Phase 1b trial for ulcerative colitis (UC) with no serious adverse events.
- Company advancing towards a Phase 2 clinical study in UC and completing early studies in functional small bowel disorders (FSCD).
The big picture
Palisade Bio's participation in the Piper Sandler Virtual Novel Targets in Immunology Symposium underscores the growing interest in targeted immunology therapies. The company's differentiated prodrug platform aims to address the tolerability limitations of systemic PDE4 inhibitors, positioning it as a key player in the treatment of inflammatory and fibrotic diseases. The upcoming Phase 2 clinical study in UC will be critical in validating the company's approach and attracting further investment.
What we're watching
- Clinical Development
- The pace at which Palisade Bio advances its Phase 2 clinical study in UC and the potential therapeutic benefits of PALI-2108 across inflammatory bowel disease indications.
- Market Positioning
- How Palisade Bio differentiates itself in the competitive immunology space with its targeted PDE4 inhibitor prodrug platform.
- Investor Sentiment
- The impact of the upcoming fireside chat and investor meetings on Palisade Bio's stock performance and market perception.
Related topics